WorthPointe LLC Acquires 112 Shares of Johnson & Johnson (NYSE:JNJ)

WorthPointe LLC grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 5.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 2,019 shares of the company’s stock after purchasing an additional 112 shares during the period. WorthPointe LLC’s holdings in Johnson & Johnson were worth $358,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. BlackRock Inc. grew its position in Johnson & Johnson by 2.6% during the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after acquiring an additional 4,982,885 shares during the last quarter. State Street Corp grew its position in Johnson & Johnson by 1.8% during the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after acquiring an additional 2,492,359 shares during the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after acquiring an additional 1,084,834 shares during the last quarter. Norges Bank bought a new stake in Johnson & Johnson during the 4th quarter worth $4,172,929,000. Finally, Legal & General Group Plc grew its position in Johnson & Johnson by 5.8% during the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock worth $2,980,062,000 after acquiring an additional 948,306 shares during the last quarter. Institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Stock Up 1.0 %

Shares of NYSE:JNJ opened at $174.59 on Thursday. The company has a market capitalization of $459.42 billion, a price-to-earnings ratio of 25.41, a P/E/G ratio of 3.31 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.14. The business’s 50-day moving average is $175.57 and its 200-day moving average is $174.49. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.48 EPS. Equities research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. UBS Group reduced their price objective on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Citigroup cut their target price on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. SVB Leerink cut their target price on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Morgan Stanley lifted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.